8-K12G3 filed November 19, 2024, 6:59 PM ET ticker PTHS CIK 0001919246

other material confidence high sentiment neutral materiality 0.50

Channel Therapeutics completes reincorporation from Delaware to Nevada; stockholder rights change

Pelthos Therapeutics Inc.

Chromocell Therapeutics merged into wholly-owned Nevada subsidiary Channel Therapeutics; all shares converted 1:1.
Company name changed to Channel Therapeutics Corporation; ticker remains CHRO on NYSE American.
Governing law shifts from DGCL to NRS; stockholder rights may differ as described in proxy statement filed Sept 26, 2024.
Existing directors and officers remain; all prior liabilities assumed by Nevada corporation.
Indemnification agreements updated to reflect Nevada law.

item 1.01 item 2.03 item 3.03 item 5.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Pelthos Therapeutics Inc.: Changed company name to Channel Therapeutics Corporation as part of reincorporation (effective 2024-11-18).

Change: charter amendment
Effective: 2024-11-18

Exact text from the filing

As a result of the Reincorporation, as of the Effective Time, the Predecessor Registrant changed its name to “Channel Therapeutics Corporation” (the “ Name Change ”) pursuant to the Nevada Articles and Nevada Charter, filed with the with the Secretary of State of the State of Nevada on November 18, 2024 and November 5, 2024, respectively.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Pelthos Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001753926-24-001960

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.